Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151164 · ClinicalTrials.gov registry record · Phase 2
Thymic Tolerance in Pediatric Heart Transplantation
A Phase 2 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00151164 is a Phase 2 study that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 48 participants.
The verdict
NCT00151164, a Phase 2 study, was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The investigators hypothesize that injecting donor bone marrow cells into the recipient thymus gland at the time of heart transplantation in children will prove to be feasible and safe. They further hypothesize that recipients receiving donor bone marrow will experience less acute rejection events with reduced long-term requirements for immunosuppressive medications when compared to controls who do not receive marrow but who are managed under an identical immunosuppressive protocol.
Interventions
- PROCEDURE donor bone marrow cell injection into thymus gland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151164
The ClinicalTrials.gov registry entry for NCT00151164 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which donor bone marrow cell injection into thymus gland is the first listed.
NCT00151164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151164 about?
NCT00151164 is a clinical study titled "Thymic Tolerance in Pediatric Heart Transplantation". The investigators hypothesize that injecting donor bone marrow cells into the recipient thymus gland at the time of heart transplantation in children will prove to be feasible and safe. They further hypothesize that recipients receiving donor bone marrow will experience less acute rejection events w...
What is the current status of trial NCT00151164?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2004-04. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00151164?
The interventions under investigation include: donor bone marrow cell injection into thymus gland (PROCEDURE).
Who is sponsoring clinical trial NCT00151164?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.